8-K: SCWorx Receives Nasdaq Partial Compliance Letter

SCWorx Corp. announced it has received a partial compliance letter from the Nasdaq Hearings Panel, confirming it met the first benchmark of its plan to regain continued listing on The Nasdaq Capital Market.

Summary

• SCWorx Corp. has received a partial compliance letter from the Nasdaq Hearings Panel, indicating it has met the first condition of its plan to remain listed on The Nasdaq Capital Market.
• The company must still achieve a closing bid price of at least $1.00 per share for a minimum of twenty consecutive trading days.
• Key deadlines include obtaining shareholder approval for a reverse stock split (RSS) by July 22, 2026, effecting the split by August 3, 2026, and demonstrating the minimum bid price compliance by August 28, 2026.
• The Nasdaq Hearings Panel granted SCWorx continued listing subject to these compliance conditions and reserves the right to reconsider if circumstances change.
• SCWorx's CEO, Tim Hannibal, stated that maintaining the Nasdaq listing is a strategic priority while the company focuses on expanding customer relationships and its data management platform.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, as the company has met an initial compliance milestone. However, significant hurdles remain, and success is not guaranteed, tempering the overall sentiment.

Positives

• Received a partial compliance letter from Nasdaq Hearings Panel, confirming the first benchmark of the compliance plan has been met.
• Granted continued listing on The Nasdaq Capital Market, subject to specific compliance conditions.
• The company is actively working to meet all Nasdaq Listing Rules for re-listing.
• CEO expresses commitment to regaining Nasdaq listing as a strategic priority.

Negatives

• The company was previously removed from the Nasdaq Stock Market on April 14, 2026, for failing to meet the minimum bid price requirement.
• The company must still demonstrate compliance with the minimum bid price rule ($1.00 for 20 consecutive trading days) by August 28, 2026.
• There is no assurance that the company will be successful in regaining full compliance.
• The Nasdaq Hearings Panel reserves the right to reconsider the continued listing if developments make it inadvisable.

Risks

• Failure to achieve a closing bid price of at least $1.00 per share for a minimum of twenty consecutive trading days by August 28, 2026.
• Failure to obtain shareholder approval for a reverse stock split by July 22, 2026.
• Failure to effect a reverse stock split by August 3, 2026.
• Any material changes to the compliance plan or events that affect the company's ability to satisfy the granted exception could lead to reconsideration of the listing.
• The Nasdaq Hearings Panel may revoke the continued listing if circumstances change and it deems it inadvisable.

Future Outlook

The company intends to take all necessary actions to satisfy the conditions established by the Nasdaq Hearings Panel to regain compliance and will continue to keep investors informed of its progress. However, there can be no assurance of success.

Management Comments

• "We appreciate the Panels continued consideration and for the opportunity to continue our Nasdaq listing while we execute the next phases of our compliance plan," said Tim Hannibal, President and Chief Executive Officer of SCWorx.
• "Maintaining our Nasdaq listing remains a strategic priority as we continue to focus on expanding customer relationships, advancing our healthcare supply chain data management platform, and creating long-term value for shareholders."

Industry Context

StockSavvy.ai notes that maintaining a listing on major exchanges like Nasdaq is crucial for companies in the healthcare technology sector to access capital, enhance credibility, and attract investors. Delisting can significantly hinder growth prospects and increase the cost of capital. SCWorx's efforts to regain compliance are critical for its continued operations and strategic initiatives in the competitive healthcare data management space.

Stakeholder Impact

• Shareholders: The continued listing on Nasdaq is positive for shareholders, providing liquidity and potential for future value appreciation. Failure to comply could lead to delisting, negatively impacting share value and liquidity.
• Employees: Maintaining Nasdaq listing can contribute to employee morale and confidence in the company's stability and future prospects.
• Creditors: A stable stock listing can indirectly support the company's creditworthiness by demonstrating operational viability and access to capital markets.

Next Steps

• Obtain shareholder approval for a reverse stock split by July 22, 2026.
• Effect a reverse stock split by August 3, 2026.
• Demonstrate compliance with the minimum bid price rule (closing bid price at or above $1.00 for 20 consecutive trading days) by August 28, 2026.
• Continue to focus on expanding customer relationships and advancing the healthcare supply chain data management platform.

Key Dates

Recommendation

The company has made progress towards regaining Nasdaq compliance, which is a positive step. However, significant conditions remain, including a reverse stock split and sustained bid price improvement, with no guarantee of success. Therefore, a 'hold' recommendation is appropriate pending further developments and confirmation of sustained compliance.

Keywords

Nasdaq compliance, Minimum Bid Price Rule, Reverse Stock Split, Continued Listing, Delisting Appeal, Nasdaq Capital Market, Healthcare Data Management, Supply Chain Solutions